![赛琳生物制药(老挝)有限公司[官网]](/skin/img/logo.png){kind=logo}
Solid Preparation
Lenvatinib
Lenvatinib, , codename: E7080, by the Japanese Eisai (Eisai) company, is a kind of multiple target receptor tyrosine kinase (RTK) inhibitors, inhibits VEGFR1, VEGFR2 and VEGFR3, may also inhibit other and pathological angiogenesis, tumor growth and cancer progression related RTK, including fibroblast growth factor (FGF) receptor FGFR1, 2 and 4 and platelet derivation growth factor receptor alpha (PDGFR alpha), KIT and RET.
Indications: for the patients with tumor
Specification: 4 mg * 30 grains
Unit: box
Retail price: $250
Note: Lenvatinib a multiple target receptor tyrosine kinase (RTK) inhibitors
Indications: for the patients with tumor
Specification: 4 mg * 30 grains
Unit: box
Retail price: $250
Note: Lenvatinib a multiple target receptor tyrosine kinase (RTK) inhibitors